Recent blog posts
DrugDeal Decode
4 min read
Exploring the Latest CSF-1R inhibitor Deal by Abbisko Therapeutics: A Guide to Rapidly Accessing Transaction Insights
13 January 2024
Abbisko Therapeutics entered into an exclusive license deal with Merck, Germany, for its CSF-1R inhibitor, Pimicotinib (ABSK021).
DrugDeal Decode
4 min read
Exploring the Latest c-MET ADC Deal by MediLink Therapeutics: A Guide to Rapidly Accessing Transaction Insights
13 January 2024
On Jan 2, 2024, MediLink Therapeutics and Roche entered a global deal to develop YL211, an ADC targeting c-MET for solid tumors.
DrugDeal Decode
4 min read
Exploring the Latest B7-H3 ADC Deal by Hansoh Pharma International Limited: A Guide to Rapidly Accessing Transaction Insights
13 January 2024
On Dec 20, 2023, Hansoh Pharma and GSK unveiled an exclusive deal for the ADC new drug HS-20093, a Hansoh innovation.
DrugDeal Decode
4 min read
Exploring the Latest AGT siRNA Deal by Sanegene Bio (Suzhou): A Guide to Rapidly Accessing Transaction Insights
13 January 2024
Innovent Biologics and Sanegene Bio (Suzhou) announced their partnership to co-develop SGB-3908, an siRNA drug targeting AGT for hypertension treatment.
DrugDeal Decode
4 min read
Exploring the Latest PCSK9 siRNA Deal by Suzhou Ribo Life Science: A Guide to Rapidly Accessing Transaction Insights
26 December 2023
Suzhou Ribo Life Science recently inked a deal with Qilu Pharmaceutical, granting them rights to develop, produce, and market PCSK9 inhibitor drug RBD7022 (SR043) in Greater China.